



دلالة الصحية
Dallah Health

DALLAH HEALTHCARE COMPANY

(A Saudi Joint Stock Company)

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

For the three-month and six-month periods ended 30 June 2023

together with the

INDEPENDENT AUDITORS' REVIEW REPORT

DALLAH HEALTHCARE COMPANY

A Saudi Joint Stock Company

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)For the three-month and six-month periods ended 30 June 2023

Contents**Page(s)**

Independent Auditors' report on review of condensed consolidated interim financial statements

1-2

Condensed Consolidated Interim Financial Statements:

Condensed consolidated statement of financial position

3

Condensed consolidated statement of profit or loss

4

Condensed consolidated statement of comprehensive income

5

Condensed consolidated statement of changes in equity

6

Condensed consolidated statement of cash flows

7

Notes to the condensed consolidated interim financial statements

8-25



KPMG Professional Services

Riyadh Front, Airport Road
P. O. Box 92876
Riyadh 11663
Kingdom of Saudi Arabia
Commercial Registration No 1010425494

Headquarters in Riyadh

كي بي إم جي للاستشارات المهنية

واجهة الرياض، طريق المطار
صندوق بريد ٩٢٨٧٦
الرياض ١١٦٦٣
المملكة العربية السعودية
سجل تجاري رقم ١٠١٠٤٢٥٤٩٤

المركز الرئيسي في الرياض

Independent auditor's report on review of condensed consolidated interim financial statements

To the Shareholders of Dallah Healthcare Company (Saudi Joint Stock Company)

Introduction

We have reviewed the accompanying 30 June 2023 condensed consolidated interim financial statements of **Dallah Healthcare Company ("the Company")** and its subsidiaries ("**the Group**") which comprise:

- the condensed consolidated statement of financial position as at 30 June 2023;
- the condensed consolidated statement of profit or loss for the three-month and six-month periods ended 30 June 2023;
- the condensed consolidated statement of comprehensive income for the three-month and six-month periods ended 30 June 2023;
- the condensed consolidated statement of changes in equity for the six-month period ended 30 June 2023;
- the condensed consolidated statement of cash flows for the six-month period ended 30 June 2023; and
- the notes to the condensed consolidated interim financial statements.

Management is responsible for the preparation and presentation of these condensed consolidated interim financial statements in accordance with IAS 34, 'Interim Financial Reporting' that is endorsed in the Kingdom of Saudi Arabia. Our responsibility is to express a conclusion on these condensed consolidated interim financial statements based on our review.

Scope of review

We conducted our review in accordance with the International Standard on Review Engagements 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' that is endorsed in the Kingdom of Saudi Arabia. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Independent auditor's report on review of condensed consolidated interim financial statements

To the Shareholders of Dallah Healthcare Company (Saudi Joint Stock Company) (continued)

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying 30 June 2023 condensed consolidated interim financial statements of **Dallah Healthcare Company** and its subsidiaries are not prepared, in all material respects, in accordance with IAS 34, 'Interim Financial Reporting' that is endorsed in the Kingdom of Saudi Arabia.

KPMG Professional Services



Fahad Mubark Aldossari
License No. 469

Riyadh on: 22 Muharram 1445H
Corresponding to: 9 August 2023

DALLAH HEALTHCARE COMPANY

A SAUDI JOINT STOCK COMPANY

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

(All amounts in Saudi Riyals unless otherwise stated)

		As at 30 June 2023 (Unaudited)	As at 31 December 2022 (Audited)
	Notes		
ASSETS			
Non-current assets			
Property and equipment	5	2,871,638,932	2,847,131,297
Right-of-use assets	6	48,826,928	49,381,970
Intangible assets and goodwill	7	201,680,578	203,506,316
Equity-accounted investees	8	1,564,805,917	209,503,500
Financial assets at fair value through other comprehensive income		452,894	306,771,366
Non-current assets		4,687,405,249	3,616,294,449
Current assets			
Inventories	9	233,524,172	255,235,067
Unbilled revenue		13,284,850	12,777,015
Due from related parties	10(i)	10,319,533	7,029,208
Prepayments and other current assets		150,268,786	114,012,203
Trade receivables	11	766,726,041	677,075,769
Cash and cash equivalents	12	238,256,425	237,944,913
Current assets		1,412,379,807	1,304,074,175
TOTAL ASSETS		6,099,785,056	4,920,368,624
EQUITY AND LIABILITIES			
Equity			
Share capital	1, 8.4	976,811,660	900,000,000
Share premium	8.4	1,027,432,988	61,142,305
Statutory reserve		93,614,972	93,614,972
Retained earnings		1,035,454,583	921,067,917
Fair value reserve		(333,496)	14,026,152
Equity attributable to owners of the Company		3,132,980,707	1,989,851,346
Non-controlling interests		257,206,504	242,234,269
Total equity		3,390,187,211	2,232,085,615
LIABILITIES			
Non-current liabilities			
Long-term murabaha financing	13	1,405,963,841	1,529,290,588
Long-term lease liabilities	6	27,769,262	26,485,416
Employee benefits		260,430,455	244,431,963
Long-term payables		2,731,960	3,307,284
Non-current liabilities		1,696,895,518	1,803,515,251
Current liabilities			
Current portion of long-term murabaha financing	13	243,149,200	226,482,816
Short-term murabaha financing	13	224,321,617	179,408,781
Short-term lease liabilities	6	14,584,010	15,826,936
Short-term retentions		6,564,660	7,082,991
Trade payables		253,116,416	248,205,952
Due to related parties	10(ii)	1,511,435	1,421,841
Accrued expenses and other current liabilities		179,073,564	155,238,754
Provision for zakat	14	41,540,842	43,344,687
Dividends payable	19	48,840,583	7,755,000
Current liabilities		1,012,702,327	884,767,758
Total liabilities		2,709,597,845	2,688,283,009
Total equity and liabilities		6,099,785,056	4,920,368,624

The accompanying notes from 1 to 21 form an integral part of these condensed consolidated interim financial statements

DALLAH HEALTHCARE COMPANY

A Saudi Joint Stock Company

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

(All amounts in Saudi Riyals unless otherwise stated)

	Notes	For the three-month period ended		For the six-month period ended	
		30 June		30 June	
		2023	2022	2023	2022
		Unaudited	Unaudited	Unaudited	Unaudited
Revenue	15	670,416,413	583,819,283	1,387,057,371	1,193,218,507
Cost of revenue		(435,340,247)	(371,686,179)	(885,187,524)	(749,392,221)
Gross profit		235,076,166	212,133,104	501,869,847	443,826,286
Selling and marketing expenses		(12,913,508)	(9,705,204)	(27,848,067)	(21,388,878)
General and administrative expenses		(129,848,751)	(105,454,622)	(245,229,472)	(211,197,548)
Impairment loss on trade receivables and other current assets	11	(4,460,557)	(294,714)	(8,444,512)	(4,636,119)
Other income		15,072,400	4,219,284	20,655,712	9,430,937
Operating profit		102,925,750	100,897,848	241,003,508	216,034,678
Finance cost		(29,883,835)	(14,647,025)	(58,380,346)	(25,597,229)
Share of results from equity accounted investees	8	(6,218,104)	(7,467,974)	(8,226,684)	(17,923,357)
Profit for the period before zakat		66,823,811	78,782,849	174,396,478	172,514,092
Zakat	14	(6,023,756)	(4,737,112)	(11,757,476)	(11,570,445)
Profit for the period		60,800,055	74,045,737	162,639,002	160,943,647
Profit for the period attributable to:					
Owners of the Company		53,005,997	69,521,303	147,666,767	152,151,556
Non-controlling interests		7,794,058	4,524,434	14,972,235	8,792,091
		60,800,055	74,045,737	162,639,002	160,943,647
Earnings per share	16	0.54	0.77	1.52	1.69

The accompanying notes from 1 to 21 form an integral part of these condensed consolidated interim financial statements

DALLAH HEALTHCARE COMPANY

A Saudi Joint Stock Company

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

(All amounts in Saudi Riyals unless otherwise stated)

	For the three-month period ended 30 June		For the six-month period ended 30 June	
	2023 (unaudited)	2022 (unaudited)	2023 (unaudited)	2022 (unaudited)
Profit for the period	60,800,055	74,045,737	162,639,002	160,943,647
Other comprehensive income:				
<u>Items that will not be reclassified to profit or loss</u>				
Revelation (loss) / gain of financial assets at fair value through other comprehensive income	(46,616)	6,218	1,200,834	3,637,711
Other comprehensive income for the period	(46,616)	6,218	1,200,834	3,637,711
Total comprehensive income for the period	60,753,439	74,051,955	163,839,836	164,581,358
Total comprehensive income for the period attributable to:				
Owners of the Company	52,959,381	69,527,521	148,867,601	155,789,267
Non-controlling interests	7,794,058	4,524,434	14,972,235	8,792,091
	60,753,439	74,051,955	163,839,836	164,581,358

The accompanying notes from 1 to 21 form an integral part of these condensed consolidated interim financial statements

DALLAH HEALTHCARE COMPANY

A Saudi Joint Stock Company

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

(All amounts in Saudi Riyals unless otherwise stated)

	Share capital	Share premium	Statutory reserve	Retained earnings	Fair value reserve	Total shareholders' equity	Non-controlling interests	Total equity
For the period ended 30 June 2023								
As at 1 January 2023 (Audited)	900,000,000	61,142,305	93,614,972	921,067,917	14,026,152	1,989,851,346	242,234,269	2,232,085,615
Profit for the period	--	--	--	147,666,767	--	147,666,767	14,972,235	162,639,002
Other comprehensive income for the period	--	--	--	--	1,200,834	1,200,834	--	1,200,834
Total comprehensive income for the period	--	--	--	147,666,767	1,200,834	148,867,601	14,972,235	163,839,836
Transactions with owners of the Company								
Capital increase (notes 1 , 8.4)	76,811,660	--	--	--	--	76,811,660	--	76,811,660
Share premium increase (note 8.4)	--	966,290,683	--	--	--	966,290,683	--	966,290,683
Dividends issued (Note 19)	--	--	--	(48,840,583)	--	(48,840,583)	--	(48,840,583)
Transfer from fair value reserve to retained earning	--	--	--	15,560,482	(15,560,482)	--	--	--
As at 30 June 2023 (Unaudited)	976,811,660	1,027,432,988	93,614,972	1,035,454,583	(333,496)	3,132,980,707	257,206,504	3,390,187,211
For the period ended 30 June 2022								
As at 1 January 2022 (Audited)	900,000,000	61,142,305	66,168,590	839,816,644	(336,969)	1,866,790,570	229,285,247	2,096,075,817
Profit for the period	--	--	--	152,151,556	--	152,151,556	8,792,091	160,943,647
Other comprehensive income for the period	--	--	--	--	3,637,711	3,637,711	--	3,637,711
Total comprehensive income for the period	--	--	--	152,151,556	3,637,711	155,789,267	8,792,091	164,581,358
As at 30 June 2022 (Unaudited)	900,000,000	61,142,305	66,168,590	991,968,200	3,300,742	2,022,579,837	238,077,338	2,260,657,175

The accompanying notes from 1 to 21 form an integral part of these condensed consolidated interim financial statements

DALLAH HEALTHCARE COMPANY

A Saudi Joint Stock Company

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(All amounts in Saudi Riyals unless otherwise stated)

	Notes	For the six-month period ended 30 June	
		2023 (Unaudited)	2022 (Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES			
Profit for the period before zakat		174,396,478	172,514,092
Adjustments:			
Depreciation on property and equipment	5	48,221,284	46,696,058
Depreciation on right-of-use assets	6	10,355,450	10,306,351
Amortization on intangible assets	7	1,827,226	1,616,923
Employee benefits charge		23,904,173	20,513,884
Provision on obsolete and slow-moving inventory	9	894,557	63,319
Impairment loss on trade receivables	11	8,444,512	4,636,119
Loss on sale of property and equipment		278,319	15,160
Share of results from equity accounted investees	8	8,226,684	17,923,357
Finance cost		58,380,346	25,597,229
Changes in operating assets and liabilities:			
Inventories		20,816,338	(21,320,847)
Unbilled revenue		(507,835)	(6,954,033)
Trade receivables		(98,094,784)	(144,041,030)
Prepayments and other current assets		(36,256,583)	(11,385,219)
Related parties, net		(3,200,731)	(3,720,570)
Trade payables		4,910,464	13,190,834
Short term retentions		(518,331)	(1,832,853)
Accrued expenses and other current liabilities		21,930,227	19,074,195
Cash generated from operating activities		244,007,794	142,892,969
Zakat paid		(13,561,321)	(15,717,762)
Employees' benefits paid		(7,905,682)	(11,141,741)
Net cash generated from operating activities		222,540,791	116,033,466
CASH FLOWS FROM INVESTING ACTIVITIES			
Acquisition of property and equipment	5	(73,007,238)	(68,458,496)
Acquisition of intangible assets	7	(1,488)	(288,000)
Proceeds from the disposal of property and equipment		--	837,370
Acquisition related cost of equity-accounted investee	8.4	(13,757,452)	--
Acquisition of financials assets at fair value through other comprehensive income		--	(314,269)
Net consideration paid to acquire subsidiary		--	(11,225,616)
Dividends received from equity-accounted investees	8.2	850,000	--
Net cash used in investing activities		(85,916,178)	(79,449,011)
CASH FLOWS FROM FINANCING ACTIVITIES			
Proceeds from Murabaha financing	13	84,861,952	14,000,000
Repayment of Murabaha financing	13	(146,609,479)	(90,930,333)
Payment of lease liabilities	6	(8,586,021)	(8,084,848)
Dividend paid		(7,755,000)	--
Long-term payable		(575,324)	(86,025)
Finance cost paid		(57,649,229)	(24,798,655)
Net cash used in financing activities		(136,313,101)	(109,899,861)
Net change in cash and cash equivalents		311,512	(73,315,406)
Cash and cash equivalents at beginning of the period		237,944,913	208,079,114
Cash and cash equivalents at end of the period	12	238,256,425	134,763,708
Non-cash transactions:			
Additions to right of use assets	6	12,088,025	12,989,541
Increase in share capital due to acquisition of equity-accounted investees	1, 8.4	76,811,660	--
Increase in share premium due to acquisition of equity-accounted investees	8.4	966,290,683	--
Transfer of financials assets at FVOCI to equity-accounted investees	8.4	307,519,306	--

The accompanying notes from 1 to 21 form an integral part of these condensed consolidated interim financial statements

DALLAH HEALTHCARE COMPANY

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(For the three-month and six-month periods ended 30 June 2023 unaudited)

All amounts are presented in Saudi riyals unless otherwise indicated

1. REPORTING ENTITY

Dallah Healthcare Company (the "Company") was established as a Limited Liability Company, registered in the Kingdom of Saudi Arabia under commercial registration number 1010128530 dated 13 Rabi Al-Akhar 1415H (corresponding to 18 September 1994).

On 14 Jumada Al-Awwal 1429H (corresponding to 20 May 2008), the Company's Board of Directors converted Dallah Healthcare Company as a Saudi Closed Joint Stock Company. The Company became a listed Company in the Saudi Capital Market Authority on 04 Safar 1434H (corresponding to 17 December 2012). The name of the Company was changed from "Dallah Healthcare Holding Company" to "Dallah Healthcare Company" based on the approval of Extraordinary General Assembly held on 16 Safar 1438H (corresponding to 16 November 2016) after completion of all legal formalities.

The objectives of the Company represent in operate, manage and maintain the healthcare entities, wholesale medicines and retail of medical and surgical equipment, prosthetics and devices for the disabled, hospital equipment and manufacturing medicines, pharmaceuticals, herbals, health, cosmetics, detergents, disinfectants and packaging in the Kingdom of Saudi Arabia.

The Company's registered office is located at King Fahad Road, Riyadh, Kingdom of Saudi Arabia.

Share Capital

The authorized, issued and paid-up share capital of the Company is SR 976,811,660 (31 December 2022: SR 900,000,000) consisting of 97,681,166 shares (31 December 2022: 90,000,000) of SR 10 each.

On 03 Jumada II, 1444H (corresponding to 27 December 2022), the Extraordinary General Assembly meeting approved to increase the Company's capital from SR 900 million to SR 976.81 million (90 million shares to 97.6 million shares). On 23 Jumada II, 1444H (corresponding to 16 January 2023), the Company issued 7,681,166 new ordinary shares in favor of Kun Investment Holding Company in exchange of acquiring 14,232,690 ordinary shares owned by Kun Investment Holding Company in the International Medical Center Company as disclosed in detail in note 8. The Company's Articles of association and Commercial registration were amended accordingly.

Dallah Al Baraka Holding Company, a closed Saudi joint stock company, owns 48.64% of the Company's share capital.

2. BASIS OF ACCOUNTING

a) *Statement of compliance*

These condensed consolidated interim financial statements comprise the interim financial statements of the Company and its subsidiaries (together referred to as the 'Group').

These condensed consolidated interim financial statements have been prepared in accordance with IAS 34 'Interim Financial Reporting' that are endorsed in the Kingdom of Saudi Arabia (KSA) and other standards and pronouncements issued by the Saudi Organization for Chartered and Professional Accountants (SOCPA).

The condensed consolidated interim financial statements do not include all of the information and disclosures required for full annual consolidated financial statements and should be read in conjunction with Group's last annual consolidated financial statements as at and for the year ended 31 December 2022. Selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance since the last annual consolidated financial statements.

٢٥١

DALLAH HEALTHCARE COMPANY

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(For the three-month and six-month periods ended 30 June 2023 unaudited)

All amounts are presented in Saudi riyals unless otherwise indicated

b) Basis of preparation

These condensed consolidated interim financial statements have been prepared on a going concern basis under accrual basis of accounting and the historical cost convention except for:

- the employees' end of service benefit obligations which are measured using the projected unit credit method;
- financial assets at fair value through other comprehensive income which are measured at fair value;
- Acquisitions of equity accounted investees are measured at fair value of the consideration transferred.

c) Functional and presentation currency

These condensed consolidated interim financial statements are presented in Saudi Arabian Riyals (SR) which is also the Group's functional currency.

d) Basis of consolidation

The subsidiary companies (referred to as the "Subsidiaries") incorporated into these condensed consolidated interim financial statements are as follows:

Name of subsidiaries	Share in equity%		Country of operation and commercial register	Principal activity as per commercial registration	Capital (SR)
	30 June 2023	31 December 2022			
Dallah Pharma Company LLC	100%	100%	Kingdom of Saudi Arabia, commercial registration No.1010410613	Pharmaceutical, herbal & cosmetic distribution & manufacturing.	4,000,000
Afyaa Al-Nakheel for Supporting Services Company LLC	100%	100%	Kingdom of Saudi Arabia, commercial registration No.1010404576	Provide manpower & Support services to hospitals and medical centres.	50,000
Dallah Namar Hospital Health Company LLC	100%	100%	Kingdom of Saudi Arabia, commercial registration No.1010495218	Operating, managing, equipping and developing hospitals and healthcare facilities, medical polyclinics.	5,000,000
Dallah Medical Care Company LLC	100%	100%	Kingdom of Saudi Arabia, Commercial Registration No. 1010189420	Providing of medical services – Medical Clinic	100,000
Care Shield Holding Company (Closed Joint Stock Company) *	58.64%	58.64%	Kingdom of Saudi Arabia, commercial registration No.1010379441	Managing private hospitals, medical and diagnostic centres, and an analytical laboratory, providing medical services, purchasing lands to build buildings on, and investing these buildings by sale or rent for the benefit of the Company.	125,000,000
Makkah Medical Canter Company (Closed Joint Stock Company)	90.87%	90.87%	Kingdom of Saudi Arabia, commercial registration No. 4031021286	Practicing the activity of public hospitals	120,080,000

* Care Shield Holding Company owns the following subsidiaries:

٣١

DALLAH HEALTHCARE COMPANY

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(For the three-month and six-month periods ended 30 June 2023 unaudited)

All amounts are presented in Saudi riyals unless otherwise indicated

<u>Subsidiaries</u>	<u>Ownership percentage %</u>
1. Medical Services Projects Company ("MSPC")	100%
2. Consulting Clinics Center Company Limited ("CC")	100%
3. Modern Clinics Pharmacy Company Limited ("MCP")	100%

The basis of accounting in respect of business combination and goodwill are consistent with those used and disclosed in detail in annual consolidated financial statements for the year ended 31 December 2022.

3. USE OF JUDGEMENTS AND ESTIMATES

The preparation of these condensed consolidated interim financial statements requires management to make judgments, estimates and assumptions that affect the application of Group's accounting policies and the reported amounts of assets, liabilities, income and expenses, the actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in future periods affected.

During the preparation of these condensed consolidated interim financial statements, there have been no changes in the significant judgements made by management in applying the Group's accounting policies and the key sources of estimation and uncertainty from those which were applied to the annual audited consolidated financial statements of the Group for the year ended 31 December 2022.

The Group's financial risk management objectives and policies and the methods to determine the fair values are consistent with those disclosed in the most recent annual consolidated financial statements for the year ended 31 December 2022.

The Group follows the practice of performing actuarial valuations of the provision for employees' benefits annually at the year end.

Measurement of fair values

A number of the Group's accounting policies require the measurement of fair values, for both financial and non-financial assets and liabilities. The Group has an established control framework with respect to the measurement of fair values. This includes a valuation team that has overall responsibility for overseeing all significant fair value measurements, including Level 3 fair values, and reports directly to the chief financial officer.

The valuation team regularly reviews significant unobservable inputs and valuation adjustments. If third party information, such as broker quotes or pricing services, is used to measure fair values, then the valuation team assesses the evidence obtained from the third parties to support the conclusion that these valuations meet the requirements of the Standards, including the level in the fair value hierarchy in which the valuations should be classified.

DALLAH HEALTHCARE COMPANY

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(For the three-month and six-month periods ended 30 June 2023 unaudited)

All amounts are presented in Saudi riyals unless otherwise indicated

When measuring the fair value of an asset or a liability, the Group uses market observable data as far as possible. Fair values are categorised into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:

- **Level 1:** Uses quoted prices (unadjusted) in active markets for identical assets or liabilities.
- **Level 2:** Uses inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices).
- **Level 3:** Uses inputs for the asset or liability that are not based on observable market data (unobservable inputs). If the inputs used to measure the fair value of an asset or a liability are categorised in different levels of the fair value hierarchy, then the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement.

The Group recognises transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred.

4. SIGNIFICANT ACCOUNTING POLICIES

The significant accounting policies applied and method of computation adopted for preparation of these interim condensed consolidated financial statements are consistent with those that were applied in the Group's last annual consolidated financial statements as at and for the year ended 31 December 2022.

Some amendments to the IFRS and other new standards become effective starting from 1 January 2023, which have been explained in the Group's last annual consolidated financial statements. These amendments and standards have no material impact on these condensed consolidated interim financial statements.

31

DALLAH HEALTHCARE COMPANY

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(For the three-month and six-month periods ended 30 June 2023 unaudited)

All amounts are presented in Saudi riyals unless otherwise indicated

5. PROPERTY AND EQUIPMENT

	30 June 2023 (Unaudited)	31 December 2022 (Audited)
Cost:		
Balance at the beginning of the period/year	3,802,150,468	3,642,564,894
Additions (<i>note 5.1</i>)	73,007,238	172,691,199
Disposals	(4,100,700)	(13,205,625)
Balance at the end of the period/year	3,871,057,006	3,802,050,468
Accumulated Depreciation:		
Balance at the beginning of the period/year	955,019,171	875,079,500
Charged	48,221,284	92,537,276
Disposals	(3,822,381)	(12,597,605)
Balance at the end of the period/year	999,418,074	955,019,171
Net book value at the end of the period/year	2,871,638,932	2,847,131,297

5.1 Asset under construction

As at 30 June 2023, Capital work in process includes construction related to the expansion of Dallah Hospital Al-Nakheel amounting to SR 107 million, Dallah Namar Hospital Health Company amounting to SR 84 million and SR 33 million related to Care-shield Holding Company.

During the period ended on 30 June 2023, the Group announced a new project for a hospital on a land owned by the Group with an area of 45,000 square meters located in Al-Arid district in Riyadh. The hospital capacity of 205 beds and has the possibility of expansion in the future. As of June 30, 2023, the Group has incurred cost related to the project amounting to SR 12 million.

6. RIGHT-OF-USE ASSETS

	30 June 2023 (Unaudited)	31 December 2022 (Audited)
Cost:		
Balance at the beginning of the period/year	85,672,739	63,982,850
Additions	12,088,025	40,492,935
De-recognition and adjustments	(8,739,943)	(18,803,046)
Balance at end of the period/year	89,020,821	85,672,739
Accumulated Depreciation:		
Balance at the beginning of the period/year	36,290,769	33,983,093
Depreciation	10,355,450	18,263,466
De-recognition and adjustments	(6,452,326)	(15,955,790)
Balance at end of the period/year	40,193,893	36,290,769
Net book value as at the end of the period / year	48,826,928	49,381,970

DALLAH HEALTHCARE COMPANY

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(For the three-month and six-month periods ended 30 June 2023 unaudited)

All amounts are presented in Saudi riyals unless otherwise indicated

LEASES AS LESSEE

	30 June 2023 (Unaudited)	31 December 2022 (Audited)
Lease liabilities		
Balance at beginning of the period / year	42,312,352	21,921,107
Acquisition of a subsidiary company	--	13,692,661
Additions	7,895,824	23,259,119
Interest	731,117	2,015,564
Modifications	--	501,279
Payments	(8,586,021)	(19,077,378)
Balance at end of the period / year	42,353,272	42,312,352
Divided into		
Long-term lease liability	27,769,262	26,485,416
Short-term lease liability	14,584,010	15,826,936
	42,353,272	42,312,352

7. INTANGIBLE ASSETS AND GOODWILL

	30 June 2023 (Unaudited)	31 December 2022 (Audited)
Cost:		
Balance at the beginning of the period/year	219,132,562	212,471,064
Additions	1,488	2,304,277
Business acquisition	--	9,448,221
Disposals	--	(5,091,000)
Balance at the end of the period/year	219,134,050	219,132,562
Accumulated Depreciation:		
Balance at the beginning of the period/year	15,626,246	17,253,782
Charged	1,827,226	3,463,464
Disposals	--	(5,091,000)
Balance at the end of the period/year	17,453,472	15,626,246
Net book value at the end of the period/year	201,680,578	203,506,316

٢٣١

DALLAH HEALTHCARE COMPANY

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(For the three-month and six-month periods ended 30 June 2023 unaudited)

All amounts are presented in Saudi riyals unless otherwise indicated

8. EQUITY ACCOUNTED INVESTEEES

Equity accounted investees are as follows:

		Ownership interest in equity as at 30 June 2023	Ownership interest in equity as at 31 December 2022	Country of operation and principal place of business	30 June 2023 (Unaudited)	31 December 2022 (Audited)
Classification						
Dr. Mohammed Rashid Al-Faqih Company	Associate	31.21%	31.21%	Kingdom of Saudi Arabia	92,016,118	106,694,806
Meras Arabia Medical Holding Company*	Associate	17%	17%	Kingdom of Saudi Arabia	45,404,650	42,967,100
MEFIC Private Equity Opportunities Fund 3	Associate	41.6%	41.6%	Kingdom of Saudi Arabia	59,841,594	59,841,594
International Medical Centre Company	Associate	27.18%	8.20%	Kingdom of Saudi Arabia	1,367,543,555	--
					1,564,805,917	209,503,500

*The total holding percentage direct and indirect ownership in Meras Arabia Medical Holding Company IS 35%. The investment is equity accounted as the Group has significant influence due to common directorship.

8.1 Dr. Mohammed Rashid Al-Faqih Company

The principal activity of Dr. Mohammed Rashid Al-Faqih Company is to own, operate and maintain the hospitals and health centres. Dr. Mohammed Rashid Al-Faqih Company owns a hospital in eastern Riyadh City under the name of Dr. Mohammed Al-Faqih Hospital.

On 13 Muharram 1442H (corresponding to 1 September 2020), the operation of the first phase of the hospital began. The hospital has a capacity of 308 beds. Management expects losses during the first three years as a result of the start-up costs.

The movement in the investment is as follows:

	30 June 2023 (Unaudited)	31 December 2022 (Audited)
Balance at the beginning of the period / year	106,694,806	95,403,018
Group's share of loss	(14,678,688)	(35,681,464)
Additional capital contribution	--	46,815,000
Group's share of other comprehensive income	--	158,252
Balance at the end of the period / year	92,016,118	106,694,806

The financial information of the associate is summarized as follows:

	30 June 2023 (Unaudited)	31 December 2022 (Audited)
Current assets	160,731,136	202,371,960
Non-current assets	748,546,907	758,635,294
Current liabilities	87,006,122	99,180,402
Non-current liabilities	571,819,571	564,342,501
Loss for the period / year	(47,032,001)	(114,323,659)
Equity	250,452,350	297,484,351

DALLAH HEALTHCARE COMPANY

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(For the three-month and six-month periods ended 30 June 2023 unaudited)

All amounts are presented in Saudi riyals unless otherwise indicated

	30 June 2023 (Unaudited)	31 December 2022 (Audited)
Net assets	250,452,350	297,484,351
Percentage ownership	31.21%	31.21%
Ownership interest	78,166,178	92,844,866
Goodwill	13,849,940	13,849,940
Carrying amount of the investment	92,016,118	106,694,806

8.2 Meras Arabia Medical Holding Company

The principal activity of Meras Arabia Medical Holding Company is providing medical services in the field of dermatology and cosmetology. The Group holds 17% in Meras Arabia Medical Holding Company and has significant influence because of the meaningful presentation on the board of the investee.

The movement in the investment is as follows:

	30 June 2023 (Unaudited)	31 December 2022 (Audited)
Balance at the beginning of the period / year	42,967,100	39,903,721
Group's share of profit	3,287,550	3,626,654
Group share of result from comprehensive income	-	286,725
Dividends received	(850,000)	(850,000)
Balance at the end of the period / year	45,404,650	42,967,100

The financial information of the associate is summarized as follows:

	30 June 2023 (Unaudited)	31 December 2022 (Audited)
Current assets	49,933,051	45,473,534
Non-current assets	138,161,076	128,510,994
Current liabilities	48,407,132	45,877,694
Non-current liabilities	44,459,379	46,407,674
Profit for the period / year	19,338,529	20,300,375
Equity	95,227,616	80,889,090

	30 June 2023 (Unaudited)	31 December 2022 (Audited)
Net assets	95,227,616	80,889,090
Percentage ownership	17%	17%
Ownership interest	16,188,695	13,751,145
Goodwill	29,215,955	29,215,955
Carrying amount of the investment	45,404,650	42,967,100

DALLAH HEALTHCARE COMPANY

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(For the three-month and six-month periods ended 30 June 2023 unaudited)

All amounts are presented in Saudi riyals unless otherwise indicated

8.3 MEFIC Private Equity Opportunities Fund 3

The movement in the investment is as follows:

	30 June 2023 (Unaudited)	31 December 2022 (Audited)
Balance at the beginning of the period / year	59,841,594	50,602,847
Group's share of profit	--	9,238,747
Balance at the end of the period / year	59,841,594	59,841,594

8.4 International Medical Centre Company (IMC)

On 21 Dhul Qa'dah 1443H (corresponding to 20 June 2022), a share swap agreement was signed between Dallah Healthcare Company and Kun Investment Holding Company (KIHC) related to the process of exchanging shares owned by KIHC in the International Medical Center (IMC) for shares swap of 7,681,166 shares of Dallah Healthcare Company against 14,232,690 shares in IMC.

On 3 Jumada II 1444H (corresponding to 16 January 2023) being acquisition date, the shares agreed between the parties were transferred. As a result, Dallah Healthcare Company obtained significant influence. Accordingly, the previous holding of 8.2% (revised shareholding being 27.18%) shareholding which was classified as financial asset at fair value through other comprehensive income has been classified as equity accounted investee.

The transaction result can be summarized in the following:

a) Share capital

	30 June 2023 (Unaudited)
Number of shares owned by KIHC in IMC	14,232,690
Exchange ratio as agreed under share swap agreement	0.539
Number of shares issued by the Company	7,681,166
Par value of shares issued by the company – SR 10 per share	76,811,660
Add: the Company's' shares capital prior to acquisition	900,000,000
The Company's share capital post acquisition	976,811,660

b) Share premium

	30 June 2023 (Unaudited)
Number of shares issued by the Company	7,681,166
The Company's share price as at 16 January 2023 (date of acquisition)	135.8
Total consideration	1,043,102,343
Less: par value of share issued by the Company – 10 Riyals per share	(76,811,660)
Share premium of the Group	966,290,683
Add : the share premium prior to acquisition	61,142,305
Share premium post to acquisition	1,027,432,988

DALLAH HEALTHCARE COMPANY

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(For the three-month and six-month periods ended 30 June 2023 unaudited)

All amounts are presented in Saudi riyals unless otherwise indicated

c) Goodwill

At acquisition date, the Company performed a preliminary assessment of the assets and liabilities of IMC. As a result, goodwill amounting to SR 1,138 million was recognized according to the provisional amount of assets and liabilities of the Company acquired on the date of acquisition due to the incomplete study of the allocation of the purchase price. The Company is currently in the process conducting a detailed assessment of the purchase price allocation.

	As on 16 January 2023 (Unaudited)
Fair value of investment in financial assets – previously classified as FVOCI	307,519,306
Consideration to acquire additional interest	1,056,859,801
Total investment in equity accounted investee	1,364,379,107
Provisional amounts of net acquired assets and liabilities at acquisition date (<i>refer below</i>)	(225,668,171)
Goodwill	1,138,710,936

The following table summarises the provisional amounts of net acquired assets and liabilities assumed at acquisition date:

	As on 16 January 2023 (Unaudited)
Property and equipment (net book value)	739,295,322
Right of use assets	126,305,580
Other non-current assets	131,608,471
Current assets	873,963,760
Total non-current liabilities	(482,575,598)
Trade current liabilities	(558,324,669)
Total provisional net assets acquired at acquisition date	830,272,866
Share of provisional amount of net assets acquired at the date acquisition - 27.18%	225,668,171

d) Movement in the investment and financial information:

The movement in the investment is as follows:

	30 June 2023 (Unaudited)
Balance at the beginning of the period	--
Fair value of financials assets – classified before as FVOCI	307,519,306
Acquisition through increase in share capital (<i>refer note "a" above</i>)	76,811,660
Acquisition through Share premium (<i>refer note "b" above</i>)	966,290,683
Acquisition related cost	13,757,452
Group's share of profit post acquisition	3,164,454
Balance at the end of the period	1,367,543,555

DALLAH HEALTHCARE COMPANY

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(For the three-month and six-month periods ended 30 June 2023 unaudited)

All amounts are presented in Saudi riyals unless otherwise indicated

The financial information of the associate is summarized as follows:

	30 June 2023 (Unaudited)
Current assets	701,046,095
Non-current assets	1,028,342,711
Current liabilities	299,972,397
Non-current liabilities	587,500,961
Profit for the period	12,701,000
Equity	841,915,448

	30 June 2023 (Unaudited)
Net assets	841,915,451
Percentage ownership	27.18%
Ownership interest	228,832,619
Goodwill	1,138,710,936
Carrying amount of the investment	1,367,543,555

9. INVENTORIES

	30 June 2023 (Unaudited)	31 December 2022 (Audited)
Medical supplies and pharmaceutical items	238,015,074	258,831,412
Provision for obsolete and slow-moving inventory	(4,490,902)	(3,596,345)
	233,524,172	255,235,067

Movement in the provision of obsolete and slow-moving inventory during the period / year is as follows:

	30 June 2023 (Unaudited)	31 December 2022 (Audited)
Balance at beginning of the period / year	3,596,345	936,085
Charge	894,557	2,660,260
Balance at the end of the period / year	4,490,902	3,596,345

341

DALLAH HEALTHCARE COMPANY

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(For the three-month and six-month periods ended 30 June 2023 unaudited)

All amounts are presented in Saudi riyals unless otherwise indicated

10. RELATED PARTIES

Related parties of the Group comprise of key management personnel and associates where shareholders or the Group have control or significant influence. The Group and its related parties transact with each other as per mutually agreed terms.

<u>Name of related parties:</u>	<u>Relationship:</u>	<u>Nature of transactions</u>
Dallah Al-Barakah Holding	Ultimate Parent Company	Medical services
Dr Mohammed Rashid Al-Faqih Company	Associate	Technical Support and Medicines sales
Meraas Arabia Medical Holding Company	Associate	Dividend received
International Medical Centre Company	Associate	Technical Support
Al-Mashfa Medical	Close family member	Medical services
Adaptive TechSoft	Owned partially by shareholder	Technical Support
Jazira Capital	Other / common Directorship	Consultation
Growth Path Investment Company–Mahara	Owned by a Shareholder of one subsidiary	Recruitment services
Joud Al Hala	Other / common Directorship	Rent payments
MEFIC Private Equity Opportunities Fund 3	Associate	Dividend received
Jarir Marketing Company	Other / common Directorship	Office supplies and stationary
Iqraa Media	Other / common Directorship	Media and advertising services
Dallah Trading Company	Other / common Directorship	Air conditioning and spare parts
Dareen Travel Agency	Owned partially by shareholder	Travel tickets
Eng. Tarek Alkasabi	Chairman of Board	Management consulting
Eng. Khalid Al-Faqih	Close family member	Engineering consulting

i) Due from related parties

	30 June 2023 (Unaudited)	31 December 2022 (Audited)
Dr Mohammed Rashid Al-Faqih Company	8,195,373	5,750,770
International Medical Centre Company	920,000	--
Al-Mashfa Medical	627,721	707,455
Dallah Al-Barakah Holding	295,199	299,221
Meraas Arabia Medical Holding Company	281,240	186,867
Joud Al Hala	--	84,895
	10,319,533	7,029,208

ii) Due to related parties

	30 June 2023 (Unaudited)	31 December 2022 (Audited)
Growth Path Investment Company - Mahara	1,310,368	988,053
Dareen Travel Agency	73,149	220,279
Adaptive TechSoft	62,497	209,094
Others	65,421	4,415
	1,511,435	1,421,841

DALLAH HEALTHCARE COMPANY

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(For the three-month and six-month periods ended 30 June 2023 unaudited)

All amounts are presented in Saudi riyals unless otherwise indicated

11. TRADE RECEIVABLES

	30 June 2023 (Unaudited)	31 December 2022 (Audited)
Trade receivables	973,161,441	846,792,527
Refund liability	(131,534,927)	(98,094,564)
Net trade receivables	841,626,514	748,697,963
Impairment loss allowance (<i>note 11.1</i>)	(74,900,473)	(71,622,194)
	766,726,041	677,075,769

11.1 Movement in the allowance for impairment in respect of trade receivables during the period/year is as follows.

	30 June 2023 (Unaudited)	31 December 2022 (Audited)
Balance at the beginning of the period / year	71,622,194	75,623,078
Charge for the period / year	8,444,512	6,047,668
Written-off during the period / year	(5,166,233)	(10,048,552)
Balance at the end of the period / year	74,900,473	71,622,194

All of the above Group's trade receivables have been reviewed for indicators of impairment.

12. CASH AND CASH EQUIVALENTS

	30 June 2023 (Unaudited)	31 December 2022 (Audited)
Cash at banks	234,710,977	236,453,723
Cash in hand	3,545,448	1,491,190
	238,256,425	237,944,913

DALLAH HEALTHCARE COMPANY

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(For the three-month and six-month periods ended 30 June 2023 unaudited)

All amounts are presented in Saudi riyals unless otherwise indicated

13. MURABAHA FINANCING

	30 June 2023 (Unaudited)	31 December 2022 (Audited)
Non-current:		
Long -term Murabaha finance and loans	1,405,963,841	1,529,290,588
Current:		
Short-term Murabaha finance	224,321,617	179,408,781
Current portion of long-term Murabaha finance and loan	243,149,200	226,482,816
Total current Murabaha finance	467,470,817	405,891,597
Total Murabaha financing and loans	1,873,434,658	1,935,182,185

1. The Group has Murabaha finance contracts with local banks at a mark-up rate of SAIBOR plus agreed margin on facilities obtained. Murabaha contracts are denominated in Saudi Riyals and bear financial cost based on prevailing market price. Murabaha contracts are obtained to finance the construction of new medical facilities and hospitals under construction. Murabaha contracts are secured by promissory notes.

As at 30 June 2023, Dallah Healthcare Company and its 100% owned subsidiaries, have bank Murabaha facilities of SR 2,610 million (31 December 2022: SR 2,795 million), out of which an amount of SR 1,531 million was utilized as at 30 June 2023 (31 December 2022: SR 1,612 million), and secured by promissory notes as at 30 June 2023, with a total of SR 2,780 million (31 December 2022: SR 2,854 million).

And the Company on 25 Muharram 1443H (corresponding to 02 September 2021), has signed an agreement with Ministry of Finance to obtain long term loan amounting to SR 357 million for the period of 10 years (16 semi-annual installments) to support the Group's strategy in completing the construction of Dallah Namar Hospital. The long-term loan has been secured by two promissory notes and mortgage deed of land for Dallah Namar Hospital. Out of these loans, SR 223 million has been received till 30 June 2023 (31 December 2022: SR 223 million).

2. The Murabaha financing balance as at 30 June 2023, includes a loan pertaining to Care Shield Holding Company, a "subsidiary company", amounting to SR 117 million (31 December 2022: SR 98 million).
3. The balance of the loans as of 30 June 2023 includes a loan in the books of Makkah Medical Centre Company, a "subsidiary company", amounting to SR 2 million, which the Company obtained from the Ministry of Finance (31 December 2022: SR 2 million), the loan is secured by a mortgage deed over the hospital's land, buildings on which it is built, medical and non-medical equipment and furniture and furnishings.

The financing costs recognized which relates to the Murabaha in the condensed consolidated interim statement of profit or loss during the period ended 30 June 2023 amounted to SR 58 million (31 December 2022: SR 69 million).

Movement summary of loans and borrowings during the period / year is as follows:

	30 June 2023 (Unaudited)	31 December 2022 (Audited)
Balance at beginning of the period / year	1,935,182,185	1,867,361,251
Proceeds during the period / year	84,861,952	724,508,764
Payments made during the period / year	(146,609,479)	(656,687,830)
Balance at end of the period / year	1,873,434,658	1,935,182,185

DALLAH HEALTHCARE COMPANY

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(For the three-month and six-month periods ended 30 June 2023 unaudited)

All amounts are presented in Saudi riyals unless otherwise indicated

14. ZAKAT

The following table shows the details of zakat provision:

	30 June 2023 (Unaudited)	31 December 2022 (Audited)
Balance at the beginning of the period / year	43,344,687	23,834,863
Charge for prior year open items	--	18,541,911
Charge for the period / year	11,757,476	15,149,367
Payments made during the period / year	(13,561,321)	(14,181,454)
Balance at the end of the period / year	41,540,842	43,344,687

The Group received zakat assessments for the years from 2014 until 2018, whereby additional demand of SR 19.7 million was made by ZATCA, for which the Group filed an appeal within the due date.

ZATCA has raised additional inquiries regarding the years 2019 and 2020, and issued an initial assessment of SR 26.6 million. The assessment was objected by the company for which the company is still awaiting the authority's response.

The management, in consultation with its Zakat consultant has recognized a provision of SR 27.8 million in respect of the open items, and believe that the provision recorded is sufficient to meet any additional Zakat liability.

15. REVENUE

	For the six-month period ended	
	30 June 2023 (Unaudited)	30 June 2022 (Unaudited)
Revenue from contracts with customers		
Revenue from services	1,043,600,480	945,827,252
Revenue from sale of medicines	343,456,891	247,391,255
	1,387,057,371	1,193,218,507
Timing of revenue recognition		
Over time	598,514,705	422,494,181
At a point in time	788,542,666	770,724,326
	1,387,057,371	1,193,218,507

The revenues recorded during the period are after deducting medical rejections. All revenue earned by the Group are within Kingdom of Saudi Arabia region.

Contract balances

	30 June 2023 (Unaudited)	31 December 2022 (Audited)
Trade receivables (note 11)	766,726,041	677,075,769
Unbilled revenue	13,284,850	12,777,015

DALLAH HEALTHCARE COMPANY

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(For the three-month and six-month periods ended 30 June 2023 unaudited)

All amounts are presented in Saudi riyals unless otherwise indicated

16. BASIC AND DILUTED EARNINGS PER SHARE

Basic earnings per share ("EPS") is calculated by dividing the profit for the period attributable to ordinary equity holders of the Group by the weighted average number of ordinary shares outstanding during the period.

The diluted earnings per share is same as the basic earnings per share as the Group does not have any dilutive equity instruments and as a result diluted EPS is equal to the basic EPS For the three-month and six-month periods ended 30 June 2023.

	For the three-month period ended 30 June		For the six-month period ended 30 June	
	2023	2022	2023	2022
	Unaudited	Unaudited	Unaudited	Unaudited
Profit for the period, attributable to the ordinary shareholder	53,005,997	69,521,303	147,666,767	152,151,556
Weighted average number of ordinary shares	97,681,166	90,000,000	97,002,168	90,000,000
Basic and diluted earnings per share	0.54	0.77	1.52	1.69

The number of shares outstanding as of 30 June 2023 is 97,681,166 shares (30 June 2022: 90,000,000 shares).

17. CONTINGENCIES AND COMMITMENTS

Capital commitments

As at 30 June 2023, the Group had capital commitments that mainly relate to the construction contracts of the expansion of Dallah Hospital Al-Nakheel and the construction of Dallah Namar Hospital amounting to SR 204 million (31 December 2022: SR 85.12 million).

Contingent liabilities

i) As at 30 June 2023, the Group has potential liabilities in the form of bank guarantees amounting to SR 69 million issued on behalf of the Group in the ordinary course of business (31 December 2022: SR 40 million). The bank guarantees include a bank guarantee issued during the year 2018 to a third party on behalf of Dr. Mohammad Al-Faqih Company "an associate company" amounting to SR 17.5 million expiring on 29 October 2023.

ii) There are Letter of credits issued by the Group amounting to 30 million as at 30 June 2023 (31 December 2022: SR 40 million).

18. OPERATING SEGMENTS

As the operations of the Group are conducted in the Kingdom of Saudi Arabia, accordingly, for management purposes, the Group is organized into business units based on its products and services and has two reportable segments. Operating segments is determined based on the Group's internal reporting to the Chief Operating Decision Maker ("CODM"). The CODM has been determined to be the Chief Executive Officer as he is primarily responsible for the allocation of resources to segments and the assessment of the performance of each of the segments. The CODM uses underlying income as reviewed at monthly Executive Committee and Performance meetings as the key measure of the segments' results as it reflects the segments' performance for the period under evaluation. Revenue and segment profit is a consistent measure within the Group. The identified key segments are Medical Services/ Medicine and Pharmaceutical Products.

DALLAH HEALTHCARE COMPANY

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(For the three-month and six-month periods ended 30 June 2023 unaudited)

All amounts are presented in Saudi riyals unless otherwise indicated

Information regarding the Group's reportable segments is presented below:

Based on nature of services:

30 June 2023	Medical Services	Medicine and Pharmaceutical Products	Total (Unaudited)
Revenue	1,309,249,817	77,807,554	1,387,057,371
Cost of revenue	(833,686,138)	(51,501,386)	(885,187,524)
Gross profit	475,563,679	26,306,168	501,869,847
Operating expenses	(258,742,944)	(22,779,107)	(281,522,051)
Other income, net	19,978,951	676,761	20,655,712
Operating profit	236,799,686	4,203,822	241,003,508
Finance cost	(57,636,971)	(743,375)	(58,380,346)
Share of results from equity accounted investees	(8,226,684)	--	(8,226,684)
Zakat	(11,635,947)	(121,529)	(11,757,476)
Net profit for the period	159,300,084	3,338,918	162,639,002
As at 30 June 2023			
Total assets	5,907,097,195	192,687,861	6,099,785,056
Total liabilities	2,625,129,201	84,468,644	2,709,597,845

30 June 2022	Medical Services	Medicine and Pharmaceutical Products	Total (Unaudited)
Revenue	1,125,226,909	67,991,598	1,193,218,507
Cost of revenue	(706,685,708)	(42,706,513)	(749,392,221)
Gross profit	418,541,201	25,285,085	443,826,286
Operating expenses	(215,659,760)	(21,562,785)	(237,222,545)
Other income, net	9,051,500	379,437	9,430,937
Operating profit	211,932,941	4,101,737	216,034,678
Finance cost	(25,428,447)	(168,782)	(25,597,229)
Share of results from equity accounted investees	(17,923,357)	--	(17,923,357)
Zakat	(11,448,571)	(121,874)	(11,570,445)
Net profit for the period	157,132,566	3,811,081	160,943,647
As at 30 June 2022			
Total assets	4,545,729,178	172,327,653	4,778,056,831
Total liabilities	2,453,887,538	63,512,118	2,517,399,656

Geographical segments:

All of the Group's operating assets and principal markets of activity are located in the Kingdom of Saudi Arabia.

DALLAH HEALTHCARE COMPANY

(A Saudi Joint Stock Company)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(For the three-month and six-month periods ended 30 June 2023 unaudited)

All amounts are presented in Saudi riyals unless otherwise indicated

19. DIVIDENDS

On 01 Dhu al-Hijjah 1444 H (corresponding to 19 June 2023), the Company's Board of Directors decided to distribute interim dividends to shareholders of SR 0.5 per share, amounting to SR 48,840,583.

As a subsequent events to the financial statement, as at 20 Muharram 1445 H (corresponding to 07 August 2023), the Company's Board of Directors decided to distribute interim dividends to shareholders of SR 0.5 per share, amounting to SR 48,840,583.

20. FINANCIAL RISK MANAGEMENT

The risk management framework and policies of the Group are consistent with those used and disclosed in the annual consolidated financial statements of the Group for the year ended 31 December 2022.

21. APPROVAL OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

These condensed consolidated interim financial statements were authorized for issue by the Group's Board of Directors on 20 Muharram 1445H (Corresponding to 07 August 2023).

٢٢١